August 18, 2022 – Mayo Clinic recently announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions. The collaboration brings together science, engineering and manufacturing to advance Mayo Clinic’s vision of bringing new cures to clinical care. The focus will be on therapies derived from human sources known as biologics — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines. Therapeutics based on biologics have the potential to target exact tissues needing repair.
To support this new venture, Mayo Clinic has formed a strategic collaboration with National Resilience Inc. to establish Rochester as a center for biomanufacturing regenerative technologies.
National Resilience Inc. will collaborate with Mayo’s Center for Regenerative Medicine in Two Discovery Square within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minn.
The collaboration has these areas of focus:
- Process development expertise to advance Mayo Clinic biotherapeutics.
- Working together to attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.
- Providing cell and gene products needed for biomanufacturing early-stage therapeutics.
- Analytical testing and quality control required for manufacturing commercial grade biopharmaceuticals.
Mayo Clinic is committed to advance research, development and manufacturing in the field of cell and gene therapies.
Mayo’s goal in developing expertise in biomanufacturing new biologic-based medicines is to accelerate clinical care options that provide new hope for patients.